EGFR and non-small cell lung carcinoma: also showed that EGFR TKIs in NSCLC patients with EGFR sensitive mutations brought the ORR up as high as 66.6 %, with a median progression-free survival (mPFS) of 9.5 months and a median overall survival (mOS) of 30.5 months, as the first-line treatment.